Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result

Background: Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. Objective: To discover a plasma proteomic...

Descripción completa

Detalles Bibliográficos
Autores principales: Westwood, Sarah, Baird, Alison L., Hye, Abdul, Ashton, Nicholas J., Nevado-Holgado, Alejo J., Anand, Sneha N., Liu, Benjamine, Newby, Danielle, Bazenet, Chantal, Kiddle, Steven J., Ward, Malcolm, Newton, Ben, Desai, Keyur, Tan Hehir, Cristina, Zanette, Michelle, Galimberti, Daniela, Parnetti, Lucilla, Lleó, Alberto, Baker, Susan, Narayan, Vaibhav A., van der Flier, Wiesje M., Scheltens, Philip, Teunissen, Charlotte E., Visser, Pieter Jelle, Lovestone, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297196/
https://www.ncbi.nlm.nih.gov/pubmed/30618716
http://dx.doi.org/10.3389/fnagi.2018.00409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297196/
https://www.ncbi.nlm.nih.gov/pubmed/30618716
http://dx.doi.org/10.3389/fnagi.2018.00409

Ejemplares similares